Harbour Biomed Regains Global Rights to HBM7008
On August 9, 2024, the company announced that it had successfully won back global development and commercialization rights to HBM7008 from Cullinan Oncology. This turning point marks the return of Cullinan Oncology's exclusive license to market HBM7008 in the United States, which was originally granted to Cullinan Oncology by Platinum Pharma in February 2023.
In accordance with the mutual termination agreement, Cullinan Oncology will formally withdraw from the partnership on the significant date of November 3, 2024. In particular, the transaction does not require any refund to Cullinan Oncology of any fees collected during the previous agreement, which undoubtedly provides a more solid financial foundation for the company's future growth.
In addition, the company holds valuable rights to conduct HBM7008 clinical trials in the European Union and Australia, and has access to all clinical data generated from these trials. This arrangement provides a solid foundation for further research and development of HBM7008 worldwide.
HBM7008, as a bisspecific antibody independently developed by Platinum Pharmaceutical, is unique in that it can simultaneously target B7-H4 and 4-1BB. At present, the drug is in the key stage of phase I clinical trials, and its indication is mainly focused on the treatment of solid tumors. The full recovery of the global development and commercialization interests of HBM7008 will undoubtedly provide a broader stage for Platinum Pharma to explore further the development potential of this drug and potential commercialization opportunities.
The company said it will continue to unswervably invest in the subsequent development and commercialization of HBM7008. They are committed to bringing new treatment options to patients through unremitting efforts and contributing their own strength to the cause of human health.
2026-10-28
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Dye Phase-Out Push Opens a Bigger Window for Natural Color Solutions
-
Glyphosate Faces New UK Pressure as EU Trade Alignment Returns to the Debate
-
U.S. API Dependence Turns Pharmaceutical Ingredients Into a National Security Issue
-
Pharma Tariff Risk Pushes Global Drugmakers to Rebuild U.S. Supply Chains
-
MDI Price Surge Hits EMEAI: Is This a Market Correction or the Beginning of a Supply Crisis?
-
“Deregulation” or “Concession”? The Hidden Crisis Behind India’s Repeal of QCOs on Seven Key Petrochemicals
-
Oil-Coal Price Gap Widens! Coal Chemical Enterprises See Significant Profit Surge in H1 2026
-
China's National Narcotics Control Commission Issues Important Notice: Beware of These 8 Chemicals Being Diverted for Drug Production
-
Explosions Reported Near Saudi Aramco Headquarters as Missile Is Intercepted Over Dhahran
-
European Petrochemicals Enter 'Era of Downsizing' as Dow, TotalEnergies, Shell Exit Older Cracker Assets
Recommend Reading
-
Japanese Plastics Market Accelerates its Shifts to Recycled Materials and Bioplastics
-
Sekisui Specialty Chemicals Has Announced a Global Price Increase
-
Two Commercial Ships Confirmed Sunk Near Strait of Hormuz Within 24 Hours
-
Hormuz Disruptions Affect Nearly 20% of Global Ethylene Capacity as Polyethylene Supply Tightens
-
Houthis Claim Attacks on Saudi Aramco Facilities and Rabigh Refinery
-
Cost Volatility & Supply Tightening: PP Prices Surge and Consolidate in September
-
Business Society October 15, 2026 PC Trend Analysis: Volatility
-
Business Society October 14, 2026 BDO Trend Analysis: Volatile with a Bearish Bias
-
Premium Global Chemical Sourcing Requests (19 - 22 Mar, 2026)
-
Cost Pushes Combined with Moving Average Golden Cross: Acrylic Acid Market Strongly Holds Prices and Rises